Search results for " RISK"

showing 10 items of 3823 documents

Oncofetal gene SALL4 and prognosis in cancer: A systematic review with meta-analysis

2016

The Spalt-Like Transcription Factor 4 (SALL4) oncogene plays a central function in embryo-fetal development and is absent in differentiated tissues. Evidence suggests that it can be reactivated in several cancers worsening the prognosis. We aimed at investigating the risk associated with SALL4 reactivation for all-cause mortality and recurrence in cancer using the current literature. A PubMed and SCOPUS search until 1st September 2016 was performed, focusing on perspective studies reporting prognostic parameters in cancer data. In addition, 17 datasets of different cancer types from The Cancer Genome Atlas were considered. A total of 9,947 participants across 40 cohorts, followed-up for abo…

0301 basic medicineOncologymedicine.medical_specialtyPediatricsmedicine.medical_treatmentDiseaseTargeted therapySALL4; cancer; meta-analysis; prognosis; targeted therapy; Humans; Neoplasms; Prognosis; Transcription FactorsCancer; Meta-analysis; Prognosis; SALL4; Targeted therapy; Oncology03 medical and health sciences0302 clinical medicineSALL4Internal medicineNeoplasmsmedicinecancerHumansSALL4 cancer prognosis meta-analysis targeted therapySALL4business.industryConfoundingHazard ratiotargeted therapyConfidence intervaleye diseases3. Good healthmeta-analysis030104 developmental biologyOncology030220 oncology & carcinogenesisMeta-analysisRelative riskprognosisbusinessResearch PaperTranscription Factors
researchProduct

The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis

2018

Abstract Introduction Carboplatin is the milestone of epithelial ovarian cancer (EOC) treatment, thus response to platinum is the major prognostic factor. Among platinum-sensitive patients, 40% carry a germline or somatic BRCA1/2 mutation. In this scenario a new class of drugs, the PARP inhibitors (PARPis), produced a significant improvement in long-term disease control. In order to make an aggregate evaluation of the impact of these agents, we performed a systematic review and meta-analysis. Patients and Methods Clinical trials were selected by searching “Pubmed” database and abstracts from major cancer meetings. We considered the January 2008 - April 2018 time frame. Progression free surv…

0301 basic medicineOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase Inhibitorslaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawOvarian cancerInternal medicinemedicineHumansMeta-analysiProgression-free survivalAdverse effectOvarian Neoplasmsbusiness.industryHazard ratioHematologyPrognosisClinical trial030104 developmental biologyPARP inhibitorOncology030220 oncology & carcinogenesisMeta-analysisRelative riskCohortFemaleRandomized clinical trialMaintenance therapybusiness
researchProduct

Prognostic Significance of Survivin Expression in Patients with Ovarian Carcinoma: A Meta-Analysis

2021

Background: Survivin belongs to the protein family of inhibitors of apoptosis (IAP) and is a regulator of the cell cycle and apoptosis. The aim of this study was to assess the clinical and prognostic significance of expression survivin in patients with ovarian cancer. Methods: We systematically searched for articles in PubMed, the American Chemical Society (Publications), Medline, the Royal Society of Chemistry, Scopus and the Web of Science. Patient clinical data, overall survival (OS), disease-free survival (DFS), and survivin expression were extracted from individual studies. We performed statistical analysis using the STATA 16 package. Eighteen publications containing data from 2233 pat…

0301 basic medicineOncologymedicine.medical_specialtylcsh:MedicineReviewsurvivin03 medical and health sciences0302 clinical medicineInternal medicineOvarian carcinomaSurvivinmedicineprognostic factorProspective cohort studybusiness.industrylcsh:RGeneral MedicineOdds ratiomedicine.diseasemeta-analysisovarian cancer030104 developmental biology030220 oncology & carcinogenesisRelative riskMeta-analysisBiomarker (medicine)Ovarian cancerbusinessJournal of Clinical Medicine
researchProduct

Legume consumption and risk of all-cause, cardiovascular, and cancer mortality in the PREDIMED study.

2018

BACKGROUND & AIMS: Limited prospective studies have examined the association between legumes consumption and mortality, whereas scarce, if at all, previous studies have evaluated such associations taking into consideration specific grain legumes. We aimed to investigate the association between total legumes consumption and grain legumes species (dry beans, chickpeas, lentils, and fresh peas) with all-cause, cardiovascular disease (CVD), cancer and other-cause mortality among elderly Mediterranean individuals at high CVD risk. METHODS: We prospectively assessed 7216 participants from the PREvención con DIeta MEDiterránea study. Dietary intake was assessed at baseline and yearly during follow…

0301 basic medicinePREDIMEDMaleDiseaseCritical Care and Intensive Care MedicineLower riskCardiovascularDiet MediterraneanCohort Studies03 medical and health sciencesRisk FactorsNeoplasmsMedicineHumansProspective StudiesMortalityCàncerProspective cohort studyLegumeCancerAgedConsumption (economics)Aged 80 and over030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryHazard ratioCancerFabaceaeMiddle Agedmedicine.diseaseLegumesConfidence intervalCardiovascular DiseasesSpainFemalebusinessllegums -- ConsumDemographyFollow-Up Studies
researchProduct

Substantial fat mass loss reduces low-grade inflammation and induces positive alteration in cardiometabolic factors in normal-weight individuals

2019

AbstractThe accumulation of fat, especially in visceral sites, is a significant risk factor for several chronic diseases with altered cardiometabolic homeostasis. We studied how intensive long-term weight loss and subsequent weight regain affect physiological changes, by longitudinally interrogating the lipid metabolism and white blood cell transcriptomic markers in healthy, normal-weight individuals. The current study examined 42 healthy, young (age: 27.5 ± 4.0 years), normal-weight (body mass index, BMI: 23.4 ± 1.7 kg/m2) female athletes, of which 25 belong to the weight loss and regain group (diet group), and 17 to the control group. Participants were evaluated, and fasting blood samples…

0301 basic medicinePanniculitisPhysiologyPROTEINmarkerslcsh:MedicinebiomarkkeritBody Mass IndexSERUM0302 clinical medicineWeight losslcsh:Scienceaineenvaihdunta2. Zero hungereducation.field_of_studyMultidisciplinarytulehdusCHOLESTEROLOrgan Size3. Good healthmedicine.anatomical_structureAdipose TissueCardiovascular DiseasesBody CompositionMetabolomemedicine.symptomOBESE WOMENBODY-COMPOSITIONPopulationInflammationHDL PARTICLE-SIZEArticle03 medical and health sciencesWhite blood cellmedicineHumansMetabolomicseducationExercisekehonkoostumusbody compositionbusiness.industryBody Weightlcsh:RDISEASE RISKLipid metabolismDietHIGH-RISKREDUCTION030104 developmental biologyPHYSICAL-ACTIVITYmarkkeritinflammation3121 General medicine internal medicine and other clinical medicinelcsh:Q3111 BiomedicinebusinessBody mass indexmetabolismBiomarkers030217 neurology & neurosurgeryHomeostasisLipoproteinScientific Reports
researchProduct

A "systems medicine" approach to the study of non-alcoholic fatty liver disease

2016

a b s t r a c t The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diag- nosis criteria, and new endpoints of clinical trials).…

0301 basic medicinePathologymedicine.medical_specialtyFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Gastroenterology; HepatologySystems AnalysisSystems biologyPersonalizedPopulationDiseaseBioinformatics03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineFatty liverNAFLDFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicinemedicineHumansFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Hepatology; GastroenterologyeducationFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Disease Progression; Humans; Non-alcoholic Fatty Liver Disease; Phenotype; Risk Factors; Systems Biology; Systems Analysis; Medicine (all); Hepatology; Gastroenterologyeducation.field_of_studyHepatologybusiness.industrySystems BiologySettore MED/09 - MEDICINA INTERNAFatty liverGastroenterologyNASHHepatologymedicine.diseaseSystems medicineClinical trial030104 developmental biologyPhenotypeSystems medicineDisease ProgressionMedicine030211 gastroenterology & hepatologySteatosisbusiness
researchProduct

Association between trans fatty acid intake and overweight including obesity in 4 to 5-year-old children from the INMA study

2019

Background: Trans fatty acid (TFA) intake has been positively associated with obesity in adults, although the evidence in children is scarce. There is growing evidence that TFA of industrial or natural origin may have different effects. Objectives: We aimed to explore the association between total, industrial, and natural TFA intake and overweight including obesity in 4 to 5-year-old Spanish children. Methods: We cross-sectionally analyzed data of 1744 children aged 4 to 5 from the INMA study, a prospective mother-child cohort study in Spain. We estimated the intake of total, industrial, and natural TFA in grams per day (g/day) using a validated food frequency questionnaire and expressed it…

0301 basic medicinePediatric Obesitypediatric obesity030209 endocrinology & metabolismOverweightLogistic regressionCohort Studies03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingEnvironmental healthHumansMedicinerisk factorsProspective StudiesDietary fatschemistry.chemical_classification030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthFatty acidOdds ratioTrans Fatty AcidsDietary fats pediatric obesity risk factors trans fatty acidsmedicine.diseaseDietary FatsObesityConfidence intervalCross-Sectional StudiesQuartilechemistrySpainChild PreschoolPediatrics Perinatology and Child HealthFemalemedicine.symptomEnergy Intakebusinesstrans fatty acidsCohort studyPediatric obesity
researchProduct

Prospective risk of stillbirth and neonatal complications in twin pregnancies: systematic review and meta-analysis

2016

Twin pregnancies are at increased risk of stillbirth. Uncomplicated twin pregnancies are commonly delivered earlier to prevent stillbirth; however, there is a risk of neonatal complications associated with being born prior to 39 weeks’ gestation. The optimal gestational age for delivery in twin pregnancies is unknown and likely varies by chorionicity. The present study aimed to determine the prospective risk of stillbirth in women with uncomplicated monochorionic and dichorionic twin pregnancies, and neonatal mortality risks, when delivered beyond 34 weeks of gestation. Data on twin pregnancies that reported rates of stillbirth were obtained from MEDLINE, EMBASE, and Cochrane Library. Separ…

0301 basic medicinePediatricsNeonatal intensive care unitPerinatal DeathCochrane LibraryInfant Newborn Diseases0302 clinical medicineObstetrics and gynaecologyPregnancyRisk FactorsTwins DizygoticMedicineProspective StudiesProspective cohort studyreproductive and urinary physiologyTwin Pregnancyhealth care economics and organizations030219 obstetrics & reproductive medicineObstetricsIncidence (epidemiology)Absolute risk reductionObstetrics and GynecologyGestational ageProspective riskGeneral MedicineStillbirthfemale genital diseases and pregnancy complicationsMeta-analysisGestationFemalemedicine.medical_specialtyeducationGestational AgeTwin-to-twin transfusion syndrome03 medical and health sciences030225 pediatricsJournal ArticleHumansGynecologyPregnancybusiness.industryResearchInfant NewbornTwins Monozygoticmedicine.diseaseConfidence interval030104 developmental biologyIntensive Care NeonatalPregnancy TwinbusinessBMJ (Clinical research ed.)
researchProduct

Changes in life expectancy for cancer patients over time since diagnosis

2019

Highlights • Research question: how cancer impacts on LE changes during patients’ entire life • LE increased in patients surviving the first years and decreasing thereafter. • Patients’ LE in the end approached but seldom reached the general population’s LE. • This method describes when cancer survivors’ excess risk of death became negligible. • Life expectancy indicator is easy to be understood and interpreted by patients.

0301 basic medicinePediatricsmedicine.medical_specialtycancer survivorLife expectancyCancer survivorsPopulationYLL years of life lost(ICD-O-3) international classification of diseases for oncology third revisionSocio-culturaleLife expectancy Population-based cancer registry Relative survival Cancer Cancer survivors ItalySettore MED/42 - Igiene Generale E ApplicataRelative survival03 medical and health sciences0302 clinical medicineHealth careMedicineeducationlcsh:Science (General)Population-based cancer registryThyroid cancerCancerRS relative survivaleducation.field_of_studylcsh:R5-920MultidisciplinaryRelative survivalbusiness.industryAbsolute risk reductionCancermedicine.diseaseLE life expectancyNHL non-Hodgkin lymphoma030104 developmental biologyYears of potential life lostItalyISTAT national institute of statistics030220 oncology & carcinogenesisLife expectancy(ICD-10) international classification of diseases tenth revisionOriginal Articlebusinesslcsh:Medicine (General)lcsh:Q1-390Journal of Advanced Research
researchProduct

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.

2016

Peroxisome proliferator-activated receptors (PPAR) are implicated in the pathology of several metabolic diseases including obesity, diabetes, and atherosclerosis. PPAR agonists exert multiple lipid modifying actions which are beneficial to the prevention of atherosclerosis. Such benefits in lipid lowering actions include improvements in atherogenic dyslipidemia that seems to be particularly expressed in individuals at higher cardiovascular (CV) risk. In addition, the favorable effects of PPAR agonists on different cardio-metabolic parameters are established in several metabolic conditions, such as diabetes mellitus, insulin resistance, and heightened systemic inflammation. The goal of this …

0301 basic medicinePeroxisome Proliferator-Activated Receptormedicine.medical_specialtyPeroxisome Proliferator-Activated ReceptorsPeroxisome proliferator-activated receptor030204 cardiovascular system & hematologyBioinformaticsSystemic inflammationPPAR agonist03 medical and health sciences0302 clinical medicineInsulin resistanceRisk FactorsCardiovascular DiseaseInternal medicineDiabetes mellitusDrug DiscoverymedicineAnimalsHumansDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationClinical Trials as TopicHypolipidemic Agentmedicine.diagnostic_testAnimalbusiness.industryRisk FactorAtherogenic dyslipidemiaCardiovascular riskmedicine.diseaseAtherosclerosisObesityThiazoles030104 developmental biologyEndocrinologyDyslipidemiachemistryCardiovascular DiseasesAtherosclerosilipids (amino acids peptides and proteins)medicine.symptomLipid profilebusinessHumanLipoproteinCurrent pharmaceutical design
researchProduct